Capricor Therapeutics, Inc. (CAPR) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Capricor Therapeutics reported revenue of $0, down 100.0% from $22.3M the year before. Net income was -$105.0M, or -$2.26 per diluted share. Operating activities generated -$69.8M of cash, leaving -$72.7M of free cash flow. At fiscal year end, Capricor Therapeutics held $355.9M in total assets against $50.2M in total liabilities, including $287.8M of cash and equivalents.
Open the full interactive Capricor Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Capricor Therapeutics Key Stats
| Share Price | $6.88 |
|---|---|
| Market Cap | $398.5M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $3.85 – $35.34 |
| Shares Outstanding | 57.9 million (basic, 2026 Q2) |
Capricor Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $310,250 | $244,898 | $2.6M | $25.2M | $22.3M | $0 |
| Operating Income | -$13.7M | -$20.9M | -$29.7M | -$24.1M | -$42.6M | -$108.1M |
| Pre-Tax Income | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105.0M |
| Income Tax | — | — | — | — | — | $1,600 |
| Net Income | -$13.7M | -$20.0M | -$29.0M | -$22.3M | -$40.5M | -$105.0M |
| Diluted EPS | -$0.88 | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 |
Capricor Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$24.6M | -$30.2M | -$33.9M | -$40.7M |
| Diluted EPS | -$0.54 | -$0.65 | -$0.59 | -$0.70 |
Capricor Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $32.7M | $34.9M | $9.6M | $14.7M | $11.3M | $287.8M |
| Current Assets | $33.7M | $36.4M | $42.9M | $50.9M | $163.4M | $322.9M |
| Total Assets | $34.6M | $41.3M | $50.1M | $58.7M | $170.5M | $355.9M |
| Current Liabilities | $3.0M | $4.1M | $23.6M | $31.3M | $21.0M | $35.8M |
| Total Long-Term Debt | $3.7M | $3.4M | $3.4M | $3.4M | — | — |
| Total Liabilities | $6.4M | $10.0M | $38.3M | $36.1M | $25.0M | $50.2M |
| Shareholders' Equity | $28.2M | $31.4M | $11.8M | $22.6M | $145.5M | $305.8M |
Capricor Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$10.1M | -$16.8M | $4.9M | -$25.6M | -$40.0M | -$69.8M |
| Cash From Investing | $5.4M | -$1.2M | -$35.1M | $5.1M | -$116.2M | $97.5M |
| Cash From Financing | $33.4M | $20.2M | $4.9M | $25.6M | $152.8M | $248.9M |
| Free Cash Flow | -$10.6M | -$18.0M | $2.9M | -$26.9M | -$41.2M | -$72.7M |
Figures from Capricor Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Capricor Therapeutics financials page for every line item.
Capricor Therapeutics Company Profile
| Ticker | CAPR |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001133869 |
Frequently Asked Questions
What was Capricor Therapeutics' revenue in fiscal 2025?
Capricor Therapeutics (CAPR) reported revenue of $0 for fiscal 2025.
What is Capricor Therapeutics' annual revenue history?
Capricor Therapeutics' annual revenue by fiscal year: 2020: $310,250; 2021: $244,898; 2022: $2.6M; 2023: $25.2M; 2024: $22.3M; 2025: $0.
What was Capricor Therapeutics' net income in fiscal 2025?
Capricor Therapeutics reported net income of -$105.0M for fiscal 2025.
What was Capricor Therapeutics' earnings per share (EPS) in fiscal 2025?
Capricor Therapeutics' diluted EPS was -$2.26 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Capricor Therapeutics generate in fiscal 2025?
Capricor Therapeutics generated -$72.7M of free cash flow in fiscal 2025.
What was Capricor Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Capricor Therapeutics reported revenue of $0.
How many shares of Capricor Therapeutics are outstanding?
Capricor Therapeutics reported a weighted average of 57.9 million basic shares outstanding in 2026 Q2.
What is Capricor Therapeutics' market cap?
Based on its latest closing price, Capricor Therapeutics (CAPR) has a market capitalization of about $398.5M.
When does Capricor Therapeutics' fiscal year end?
Capricor Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Capricor Therapeutics headquartered?
Capricor Therapeutics lists its business address in San Diego, California in its SEC filings.